Progression-free survival is a surrogate for survival in advanced colorectal cancer

被引:290
作者
Buyse, Marc
Burzykowski, Tomasz
Carroll, Kevin
Michiels, Stefan
Sargent, Daniel J.
Miller, Langdon L.
Elfring, Gary L.
Pignon, Jean-Pierre
Piedbois, Pascal
机构
[1] Int Inst Drug Dev, B-1340 Louvain, Belgium
[2] Hasselt Univ, Ctr Stat, Diepenbeek, Belgium
[3] AstraZeneca Res & Dev, Oncol Therapy Area, Macclesfield, Cheshire, England
[4] Inst Gustave Roussy, Biostat & Epidemiol Unit, Villejuif, France
[5] AstraZeneca, Oncol Therapy Area, Rueil Malmaison, France
[6] Mayo Clin, Div Biostat, Rochester, MN USA
[7] PTC Therapeut, S Plainfield, NJ USA
关键词
D O I
10.1200/JCO.2007.11.8836
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The traditional end point for assessing efficacy of first-line chemotherapies for advanced cancer is overall survival (OS), but this end point requires prolonged follow-up and is potentially confounded by the effects of second-line therapies. We investigated whether progression-free survival (PFS) could be considered a valid surrogate for OS in advanced colorectal cancer. Patients and Methods Individual patient data were available from 10 historical trials comparing fluouracil (FU) + leucovorin with either FU alone (1,744 patients) or with raltitrexed (1,345 patients) and from three validation trials comparing FU + leucovorin with or without irinotecan or oxaliplatin (1,263 patients). Correlation coefficients were estimated in historical trials between the end points of PFS and OS, and between the treatment effects on these end points. Treatment effects on OS were predicted in validation trials, and compared with the observed effects. Results In historical trials, 1,760 patients (57%) had progressed or died at 6 months, and 1,622 (52%) had died at 12 months. The rank correlation coefficient between PFS and OS was equal to 0.82 (95% Cl, 0.82 to 0.83). The correlation coefficient between treatment effects on PFS and on OS ranged from 0.99 (95% Cl, 0.94 to 1.04) when all trials were considered to 0.74 (95% Cl, 0.44 to 1.04) after exclusion of one highly influential trial. In the validation trials, the observed OS hazard ratios were within the 95% prediction intervals. A hazard ratio of 0.77 or lower in terms of PFS would predict a benefit in terms of OS. Conclusion PFS is an acceptable surrogate for OS in advanced colorectal cancer.
引用
收藏
页码:5218 / 5224
页数:7
相关论文
共 30 条
[1]  
[Anonymous], Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics
[2]  
BOBBIOPALLAVICINI E, 1993, J CHEMOTHERAPY, V5, P52
[3]   The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial [J].
Borner, MM ;
Castiglione, M ;
Bacchi, M ;
Weber, W ;
Herrmann, R ;
Fey, MF ;
Pagani, O ;
Leyvraz, S ;
Morant, R ;
Pestalozzi, B ;
Hanselmann, S ;
Goldhirsch, A .
ANNALS OF ONCOLOGY, 1998, 9 (05) :535-541
[4]   The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer [J].
Burzykowski, T ;
Molenberghs, G ;
Buyse, M .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY, 2004, 167 :103-124
[5]   Validation of surrogate end points in multiple randomized clinical trials with failure time end points [J].
Burzykowski, T ;
Molenberghs, G .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2001, 50 :405-422
[6]  
Burzykowski T., 2005, EVALUATION SURROGATE
[7]   Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis [J].
Buyse, M ;
Thirion, P ;
Carlson, RW ;
Burzykowski, T ;
Molenberghs, G ;
Piedbois, P .
LANCET, 2000, 356 (9227) :373-378
[8]  
Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49
[9]   Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer [J].
Cocconi, G ;
Cunningham, D ;
Van Cutsem, E ;
Francois, E ;
Gustavsson, B ;
van Hazel, G ;
Kerr, D ;
Possinger, K ;
Hietschold, SM .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) :2943-2952
[10]  
COX DR, 1972, J R STAT SOC B, V34, P187